Pinterest Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Pinterest Inc trades at $22.54 (market cap $12.79B), while State Street SPDR S&P Biotech ETF trades at $152.06. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Pinterest Inc nearer its low. Which is the better fit depends on your goals.
| PINS | XBI | |
|---|---|---|
Market Cap | $12.79B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $39.17 | $164.28 |
52-Week Low | $15.42 | $85.16 |
Enterprise Value | $12.69B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Trailing returns across standard periods
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →